Drug-resistant Tuberculosis (DRTB) occurs when the drugs
used to treat TB are misused or mismanaged by, WHO 2018 Examples of misuse or mismanagement
include People who do not complete a full course of TB treatment, Health care providers
prescribing the wrong treatment (the wrong dose or length of time), Drugs for proper
treatment are not available, and poor quality of drugs. The study aimed at determining
the treatment outcome of Community-Initiated Drug-Resistant Tuberculosis Patients registered between January 2017 and December 2020.in Akwa Ibom State, Nigeria. The study design was a retrospective cohort study; a
total sampling technique was employed
to review patients that were diagnosed and registered during the period of study. The demographic and clinical data of each patient were
retrieved from the DR-TB patient treatment cards, DR-TB patient treatment progress
notes from directly observed treatment short-course (DOTS) providers in the community,
the state DR-TB central register, and treatment card. Data were analyzed using Statistical Package for Social Sciences (SPSS) Software
(Version 23; SPSS, Chicago, IL, USA). The median age of clients that participated in the study
was 34 years [27- 49.5]. Most of the participants were male
(56.2%), and a greater proportion of the enrollees were all new cases (76.3%). The
some of the sociodemographic characteristics of patients that received treatment
for drug-resistant tuberculosis using the Community-Initiated
model, their health outcomes, and assessed the predictors of some of the health
Lauge C, Chesor D, Heyckendof J, Leung CC,
Udoradie Z, Dhede K., 2018, Drug-resistant tuberculosis; an uptake on disease
burden, diagnose and treatment Respirology 23(7);656-673, https://pubmed.ncbi.nlm.nih.gov/29641838/.
World Health Organization. (2021).
Tuberculosis. Available from: https://www.who.int/fact-sheet/details/tuberculosis/
Accessed on the 3rd of November 2021.
World Health Organization. Global
Tuberculosis Report. Geneva: World Health Organization; 2018. Available
WHO global TB report 2017; general, world
health organization: who, int’l team global tuberculosis program. Available
from www.who.int. Accessed on the 12th of November 2021.
World Health Organization. Global
Tuberculosis Report. Geneva: World Health Organization; 2019, Available
Monno L, Angarano G, Carbonara S, Coppola
S, Costa D, Quanl M et al., 1991, Emergency of drug-resistant mycobacterium
tuberculosis in HIV infected patient, Lancet .337(8745-852), https://dx.doi.org/10.1155%2F2007%2F986794.
Safaev K, Parpieva N, Liverko I, Yuldashev S, Dumchev K,
Gadoev J, Korotych O, Harries AD. Trends, Characteristics and Treatment
Outcomes of Patients with Drug-Resistant Tuberculosis in Uzbekistan: 2013-2018.
Int J Environ Res Public Health. 2021 Apr 27;18(9):4663. doi:
10.3390/ijerph18094663. PMID: 33925705; PMCID: PMC8124452 https://pubmed.ncbi.nlm.nih.gov/33925705/.
Akwa Ibom State History. http://www.encyclopedia.com/doc/1G2-2870600010.html.
Oyefabi A, Adelekan B, Adetisa E, Emmanuel
L, Jimoh O., 2020, Prediction of intensive phase treatment outcome among
patients with multi-drug resistant tuberculosis in Zaria- North-western
Nigeria. Journal of community medicine and primary health
M, Musa B. M, Gidado M, Nsa B, Sari U, Itabibu A.T, Jijjani IA, et al.,2019,
Determinants of mortality among patients with drug resistance tuberculosis in
northern Nigeria, plosora Plos One Journal, 14(11), e0225165, https://doi.org/10.1371/journal.pone.0225165.
Mitnick C, Bayona J, Palacios E, et al.
Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru.
N Engl J Med. 2003;348(2):119–28, https://doi.org/10.1056/nejmoa022928.
T, Bayray A, Weldearegay B (2013) Survival and prediction of mortality among
patient under multi_drug resistant tuberculosis treatment in Ethiopia, St
Peter’s specialize tuberculosis hospital, Ethiopia. Internal Journal of
pharmaceutical science and research 4(2),776. https://www.researchgate.net/profile/Theodros-Zemedu/publication/263086889.
Heller T, Lessells R. J, Wallrauch C. G,
Barnighausen T, Cook Gs, Nhlongo L, et al., 2010, Community-based treatment for
multidrug-resistant tuberculosis in rural Kirazulu-natal, South Africa. The
International Journal of Tuberculosis and Live Disease 14(14), 420-426, https://pubmed.ncbi.nlm.nih.gov/20202299/.
 Mibei DJ, Kiarie JW,
Wairia A, Kamene M, Okumu ME. Treatment outcomes of drug-resistant tuberculosis
patients in Kenya. Int J Tuberc Lung Dis. 2016 Nov;20(11):1477-1482. Doi: 10.5588/ijtld.15.0915.